HomeUK4BIO Capital Enhances Advisory Board and Investment Team

4BIO Capital Enhances Advisory Board and Investment Team

4bio capital

4BIO Capital, a London, UK-based venture capital firm investing in advanced therapies and other emerging technologies, announced two appointments to its Advisory Board and a promotion to Principal.

In details, the firm announced:

  • the appointments of biopharmaceutical industry veteran Abbas Hussain and vectorology expert Leszek Lisowski, PhD MBA to its Advisory Board, and
  • the promotion of Dr Natalie Johnston to Principal.

Abbas Hussain’s distinguished career in the global pharmaceutical industry spans over 30 years. Most recently, he was CEO of Vifor Pharma, leading the company to its sale to Australian biotech, CSL for $11.7 billion in December 2021. Prior to Vifor Pharma, Hussain held multiple roles of increasing seniority at GSK, latterly as Global President Pharmaceuticals and Vaccines, a role he held for five years. Prior to that, he held various management positions at Eli Lilly, at sites in the US, Europe, Asia and Australia. Hussain is also an independent Board member of companies including Asceneuron and Alfasigma and acts as an advisor to multiple healthcare sector-focussed private equity firms.

Leszek Lisowski is a vectorology expert with over 20 years of experience in developing and manufacturing viral vectors. He was Co-founder of Nasdaq-listed rare disease focussed gene therapy company LogicBio Therapeutics until October 2022 when the firm was acquired for $68 million by AstraZeneca. More recently, Lisowski has also established two gene therapy companies in Australia, Exigen Biotherapeutics and Sendatu Therapeutics, which focus on the unmet need in vector-based gene therapy. He currently is an Associate Professor at the University of Sydney, Australia and holds the position of Unit Head of the Translational Vectorology Research Unit at Children’s Medical Research Institute, Westmead, New South Wales, Australia. Lisowski was instrumental in securing over $135 million in funding from NSW Government to establish a clinical grade Viral Vector Manufacturing Facility (VVMF) in New South Wales.

Natalie Johnston has been with 4BIO since September of 2019, and most recently served as an Investment Associate.

4BIO Capital is a venture capital firm focused on investing in advanced therapies, including genomic medicines and other emerging technologies, to unlock the treatments of the future. Its target is to invest in, support, and grow early-stage companies developing treatments in areas of high unmet medical need, with the ultimate goal of ensuring access to these potentially curative therapies for all patients. Specifically, it looks for viable, high-quality opportunities in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome.